arrow
M

Marco Cipolli

Azienda Ospedaliera Universitaria Integrata
H指数:30
被引数:4,768

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Beyond readthrough: ataluren restores mitochondrial function and reduces oxidative stress in FANCA-mutated cells via mTOR–DRP1 modulation

超越readthrough:ataluren通过mTOR–DRP1调控恢复FANCA突变细胞的线粒体功能并降低氧化应激

2026-02-280
OAAI
Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center

意大利Elexacaftor/Tezacaftor/Ivacaftor(ELX/TEZ/IVA)的实际应用效果:一项来自囊性纤维化中心的回顾性研究

2025-12-010
OAAI
Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR

超越Trikafta:评估组织依赖性N1303K-CFTR挽救的新模型

2025-10-290
OAAI
COVID-19 in people with Cystic Fibrosis beyond the pre-omicron era: a prospective study with a specific focus on long COVID

囊性纤维化患者中奥密克戎时代前的COVID-19:一项前瞻性研究,特别关注长期COVID

2025-09-030
PRE
Ataluren improves hematopoietic and pancreatic disorders in Shwachman-Diamond syndrome patients: a compassionate program case-series

Ataluren改善了Shwachman-Diamond综合征患者的造血和胰腺功能紊乱:一项同情用药计划病例系列研究

2025-09-020
OAAI
Development of translational read-through-inducing drugs as novel therapeutic options for patients with Fanconi anemia

开发诱导翻译读码框跨越的药物作为范可尼贫血患者的新型治疗选择

2025-06-210
OAAI
ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis

Espen-espghan-ECFS囊性纤维化营养护理指南

2024-02-0123
PRE
Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations
2023-10-2625
OAAI